Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Pilot Study to Test the Efficacy and Safety of Recombinant Factor VIIa (rFVIIa, NovoSeven®) in the Treatment of Refractory Hemorrhagic Cystitis Following High Dose Chemotherapy

NCT01561352 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01561352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01561352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Pilot Study to Test the Efficacy and Safety of Recombinant Factor VIIa (rFVIIa, NovoSeven®) in the Treatment of Refractory Hemorrhagic Cystitis Following High Dose Chemotherapy
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2001
Completion date
November 30, 2003
Enrollment
7 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

haemorrhagic cystitis, other haemostasis disorder